Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Big Data Research Platform Aggregates, Interprets Molecular, Life Sciences Data

By BiotechDaily International staff writers
Posted on 29 Jul 2013
A new research platform’s Big Data technology enables users to apply genomic data from disparate sources in innovative and helpful ways across life sciences research.

Boehringer Ingelheim (Ingelheim, Germany) has signed a multiyear renewal agreement to the NextBio research platform (Santa Clara, CA, USA). The new agreement also extends the user base for NextBio across Boehringer Ingelheim’s global research organization.

“Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies and has been a user of NextBio Research for the past year,” said Saeid Akhtari, NextBio president and chief executive officer. “This expanded license and broadened access to the NextBio Research platform is a strong endorsement of our technology’s value for enabling life scientists to quickly examine and understand their data in the context of published research worldwide.

“NextBio Research provides a comprehensive platform for exploratory, preclinical and early translational research in drug discovery and biotechnology research,” Mr. Akhtari added. “Integrating proprietary analysis results with extensive curated content, NextBio enhances researchers’ ability to design experiments, test hypotheses, and validate results, leading to better target analysis, understanding of disease mechanisms, and analysis of results across species.”

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. It operates globally with 140 affiliates and more than 46,000 employees. The company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. In 2012, Boehringer Ingelheim achieved net sales of about EUR 14.7 billion. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

NextBio provides a cutting-edge scientific platform to aggregate and interpret large quantities of molecular and other life sciences data for research and clinical applications. NextBio’s platform integrates data from multiple repositories and diverse technologies by way of a unique correlation engine, which precomputes billions of significant connections between disparate public and proprietary clinical and research data. This feature enables interpretation of an individual’s molecular data.

Furthermore, the platform provides translational researchers with the capability to gaze across the clinical and molecular data of entire populations for clinical trial stratification and selection, hypotheses generation, and biomarker discovery. NextBio Clinical, which recently passed an independent HIPAA audit, is designed for seamless integration with existing clinical and research systems. Backed by highly scalable, Big Data technology, it is capable of analyzing petabytes of data. NextBio’s platform is delivered as a software as a service (SaaS) system, resulting in fast deployment and rapid return on investment.

NextBio is currently used by researchers and clinicians in over 50 top commercial and academic institutions.

Related Links:

Boehringer Ingelheim
NextBio



RANDOX LABORATORIES
SLAS - Society for Laboratory Automation and Screening
BIOSIGMA S.R.L.
comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A 3-dimensional picture reveals how the antibodies in the experimental drug Zmapp bind to Ebola virus (Photo courtesy of the Scripps Research Institute).

Electron Microscope Imaging Shows How Experimental Anti-Ebola Drug Works

Electron microscope imaging has revealed how the experimental drug ZMapp binds to the Ebolavirus and provides insights into how the drug prevents growth of the pathogen. ZMapp, which was developed by... Read more

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel

e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. Offering the potential to test... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.